PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers
Status:
Not yet recruiting
Trial end date:
2026-01-03
Target enrollment:
Participant gender:
Summary
Vonoprazan (VPZ), an oral potassium-competitive acid blocker (P-CAB) has emerged as an
alternative potent acid-suppressant.It has a faster onset of action in 1 day (3-5 days in
PPI), and is more stable in acidic condition than PPI. While many studies compared Vonoprazan
against PPI in the treatment of reflux oesophagitis, H. Pylori eradication, and gastric
ulcers; thus far, there is a paucity of data on use of Vonoprazan on bleeding peptic ulcers.
We perform a multicenter randomized controlled trial (RCT) to compare the efficacy of oral
Vonoprazan against standard high dose PPI therapy in bleeding peptic ulcers that had received
successful endoscopic haemostasis We hypothesize that in patients with bleeding peptic
ulcers, the use of acid pump inhibitors Vonoprazan would not be inferior to standard
treatment of a bolus plus high dose PPI intravenous infusion at preventing recurrent bleeding
after endoscopic haemostasis.